Related Experiment Video
Updated: Jan 31, 2026

Transoral Robotic Total Thyroidectomy and Bilateral Central Regional Lymph Node Dissection for Papillary Thyroid Carcinoma
Published on: September 15, 2023
Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating
Fei Huang1, Qing Zhang2, Wei Chen3
1Department of General Surgery, The Seventh Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China.
Objectives:
Cancer susceptibility candidate 2 (CASC2) and long noncoding RNA (lncRNA) have been identified as a tumor suppressor in colorectal, lung, renal, and stomach cancer as well as in patient gliomas, but the function of CASC2 in papillary thyroid carcinoma (PTC) is not yet clear. The present study aimed to explore the effects of CASC2 in PTC.
Methods:
The CASC2 expression was measured in PTC samples and normal tissues by using quantitative real-time polymerase chain reaction. The lentiviral vectors were used to establish CASC2 overexpression models in PTC cell lines to determine the effects of CASC2 on cell proliferation, apoptosis, migration, and invasion. A tumor xenograft animal model was used to examine the functions of overexpression CASC2.
Results:
CASC2 expression was significantly decreased in PTC tumor tissues than adjacent normal tissues. CASC2 downregulation in PTC tissues significantly correlated with the tumor size, the presence of multifocal lesions, and the advanced pathological stage. CASC2 overexpression suppressed the cell proliferation and promoted apoptosis in PTC cell lines and CASC2 overexpression resulted in the inactivation of protein kinase B (PKB/AKT) and extracellular signal-regulated kinases (ERK1/2). The regulatory effects of CASC2 on PTC cell biological behavior were further enhanced by mitogen-activated protein kinase kinase (MEK) inhibitor U0126 or AKT1/2/3 inhibitor MK-2206 2HCl. CASC2 overexpression suppressed tumor growth in PTC cells in xenograft mouse models.
Conclusion:
Our results indicated that CASC2 significantly suppressed tumorigenesis in PTC and CASC2 may serve as a novel prognostic marker or therapeutic target.
Insights
Cancer susceptibility candidate 2 (CASC2) long noncoding RNA (lncRNA) suppresses papillary thyroid carcinoma (PTC) tumorigenesis. CASC2 may serve as a prognostic marker or therapeutic target for PTC.
Area of Science:
- Molecular Biology
- Oncology
- Genetics
Background:
- Long noncoding RNAs (lncRNAs) are increasingly recognized for their roles in cancer.
- Cancer susceptibility candidate 2 (CASC2) is a lncRNA with known tumor suppressor functions in various cancers.
- The specific role of CASC2 in papillary thyroid carcinoma (PTC) remains largely unexplored.
Purpose of the Study:
- To investigate the expression and function of CASC2 in papillary thyroid carcinoma (PTC).
- To determine the potential of CASC2 as a prognostic marker or therapeutic target for PTC.
Main Methods:
- Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure CASC2 expression in PTC tissues and adjacent normal tissues.
- Lentiviral vectors were employed to create CASC2 overexpression models in PTC cell lines.
- Cell proliferation, apoptosis, migration, and invasion assays were performed, along with a tumor xenograft animal model study.
Main Results:
- CASC2 expression was significantly downregulated in PTC tissues compared to normal tissues.
- Reduced CASC2 expression correlated with larger tumor size, multifocal lesions, and advanced pathological stage.
- Overexpression of CASC2 inhibited PTC cell proliferation, promoted apoptosis, and suppressed tumor growth in vivo.
- CASC2 overexpression led to the inactivation of the AKT and ERK1/2 signaling pathways.
Conclusions:
- CASC2 acts as a tumor suppressor in papillary thyroid carcinoma (PTC).
- CASC2 warrants further investigation as a potential prognostic biomarker and therapeutic target for PTC.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
X-Inactivation
meta-Directing Deactivators: –NO2, –CN, –CHO, –⁠CO2R, –COR, –CO2H
2° Amines to N-Nitrosamines: Reaction with NaNO2
Notch Signaling Pathway
The Notch gene came into the limelight in 1914 after the discovery that its mutation in Drosophila melanogaster leads to a serrated (or "notched") wing margin phenotype. It was not...
Hedgehog Signaling Pathway

